210 related articles for article (PubMed ID: 25211656)
1. Serial surveillance of carcinoid heart disease: factors associated with echocardiographic progression and mortality.
Dobson R; Burgess MI; Valle JW; Pritchard DM; Vora J; Wong C; Chadwick C; Keevi B; Adaway J; Hofmann U; Poston GJ; Cuthbertson DJ
Br J Cancer; 2014 Oct; 111(9):1703-9. PubMed ID: 25211656
[TBL] [Abstract][Full Text] [Related]
2. Variation in Cardiac Screening and Management of Carcinoid Heart Disease in the UK and Republic of Ireland.
Dobson R; Valle JW; Burgess MI; Poston GJ; Cuthbertson DJ
Clin Oncol (R Coll Radiol); 2015 Dec; 27(12):741-6. PubMed ID: 26170123
[TBL] [Abstract][Full Text] [Related]
3. Determination of the optimal echocardiographic scoring system to quantify carcinoid heart disease.
Dobson R; Cuthbertson DJ; Jones J; Valle JW; Keevil B; Chadwick C; Poston GP; Burgess MI
Neuroendocrinology; 2014; 99(2):85-93. PubMed ID: 24603343
[TBL] [Abstract][Full Text] [Related]
4. Carcinoid Heart Disease: Prognostic Value of 5-Hydroxyindoleacetic Acid Levels and Impact on Survival: A Systematic Literature Review.
Buchanan-Hughes A; Pashley A; Feuilly M; Marteau F; Pritchard DM; Singh S
Neuroendocrinology; 2021; 111(1-2):1-15. PubMed ID: 32097914
[TBL] [Abstract][Full Text] [Related]
5. Arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours.
Kostiainen I; Karppinen N; Simonen P; Rosengård-Bärlund M; Lindén R; Tarkkanen M; Gordin D; Rapola J; Schalin-Jäntti C; Matikainen N
Endocrine; 2022 Jun; 77(1):177-187. PubMed ID: 35536452
[TBL] [Abstract][Full Text] [Related]
6. Echocardiographic and biochemical evaluation of the development and progression of carcinoid heart disease.
Denney WD; Kemp WE; Anthony LB; Oates JA; Byrd BF
J Am Coll Cardiol; 1998 Oct; 32(4):1017-22. PubMed ID: 9768727
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for the development and progression of carcinoid heart disease.
Bhattacharyya S; Toumpanakis C; Chilkunda D; Caplin ME; Davar J
Am J Cardiol; 2011 Apr; 107(8):1221-6. PubMed ID: 21296329
[TBL] [Abstract][Full Text] [Related]
8. The role of N-terminal pro-brain natriuretic peptide, chromogranin A, and 5-hydroxyindoleacetic acid in screening for carcinoid heart disease.
Johnson KKN; Stemann Lau T; Mark Dahl Baunwall S; Elisabeth Villadsen G; Guldbrand Rasmussen V; Grønbaek H; Oksjoki RK; Dam G
J Neuroendocrinol; 2023 Oct; 35(10):e13327. PubMed ID: 37574797
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular abnormalities in patients with a carcinoid syndrome.
Meijer WC; van Veldhuisen DJ; Kema IP; Van den Berg MP; Boomsma F; Willemse PH; De Vries EG
Neth J Med; 2002 Mar; 60(1):10-6. PubMed ID: 12074037
[TBL] [Abstract][Full Text] [Related]
10. Serotonin levels and 1-year mortality in patients with neuroendocrine tumors: a systematic review and meta-analysis.
Joish VN; Shah S; Tierce JC; Patel D; McKee C; Lapuerta P; Zacks J
Future Oncol; 2019 Apr; 15(12):1397-1406. PubMed ID: 30734573
[No Abstract] [Full Text] [Related]
11. The association of a panel of biomarkers with the presence and severity of carcinoid heart disease: a cross-sectional study.
Dobson R; Burgess MI; Banks M; Pritchard DM; Vora J; Valle JW; Wong C; Chadwick C; George K; Keevil B; Adaway J; Ardill JE; Anthoney A; Hofmann U; Poston GJ; Cuthbertson DJ
PLoS One; 2013; 8(9):e73679. PubMed ID: 24069222
[TBL] [Abstract][Full Text] [Related]
12. Carcinoid heart disease in patients with midgut neuroendocrine tumours.
Delhomme C; Walter T; Arangalage D; Suc G; Hentic O; Cachier A; Alkhoder S; François L; Lombard-Bohas C; Iung B; Ruszniewski P; de Mestier L
J Neuroendocrinol; 2023 Apr; 35(4):e13262. PubMed ID: 37005217
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with progression of carcinoid heart disease.
Møller JE; Connolly HM; Rubin J; Seward JB; Modesto K; Pellikka PA
N Engl J Med; 2003 Mar; 348(11):1005-15. PubMed ID: 12637610
[TBL] [Abstract][Full Text] [Related]
14. Carcinoid Heart Disease Management: A Multi-Disciplinary Collaboration.
Das S; Stockton SS; Hassan SA
Oncologist; 2023 Jul; 28(7):575-583. PubMed ID: 37209415
[TBL] [Abstract][Full Text] [Related]
15. Results of Contemporary Valve Surgery in Patients with Carcinoid Heart Disease.
Kuntze T; Owais T; Secknus MA; Kaemmerer D; Baum R; Girdauskas E
J Heart Valve Dis; 2016 May; 25(3):356-363. PubMed ID: 27989047
[TBL] [Abstract][Full Text] [Related]
16. Comparison of prognostic value of tissue Doppler imaging in carcinoid heart disease versus the value in patients with the carcinoid syndrome but without carcinoid heart disease.
Mansencal N; McKenna WJ; Mitry E; Beauchet A; Pellerin D; Rougier P; Dubourg O
Am J Cardiol; 2010 Feb; 105(4):527-31. PubMed ID: 20152249
[TBL] [Abstract][Full Text] [Related]
17. What do we know about carcinoid heart disease in the present era?
Pęczkowska M; Konsek-Komorowska SJ; Kolasińska-Ćwikła AD; Konka M; Michałowska I; Ćwikła JB
Kardiol Pol; 2022; 80(10):990-1001. PubMed ID: 36136036
[TBL] [Abstract][Full Text] [Related]
18. Echocardiography in functional midgut neuroendocrine tumors: When and how often.
Castillo JG; Naib T; Zacks JS; Adams DH
Rev Endocr Metab Disord; 2017 Dec; 18(4):411-421. PubMed ID: 29080935
[TBL] [Abstract][Full Text] [Related]
19. Carcinoid Syndrome and Carcinoid Heart Disease as Manifestations of Non-Metastatic Ovarian Neuroendocrine Tumour.
Simões-Pereira J; Wang LM; Kardos A; Grossman A
Acta Med Port; 2017 May; 30(5):421-425. PubMed ID: 28865508
[TBL] [Abstract][Full Text] [Related]
20. Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease.
Zuetenhorst JM; Korse CM; Bonfrer JM; Bakker RH; Taal BG
Br J Cancer; 2004 Jun; 90(11):2073-9. PubMed ID: 15150565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
